There are several ongoing drug trials for NAFLD/NASH therapy, including trials of obeticholic acid (OCA), elafibranor, selonsertib (SEL), apoptosis signal-regulating kinase 1 (ASK1), cenicriviroc (CVC), fibroblast growth factor (FGF)-21, Aramchol, acetyl-CoA carboxylase (ACC) inhibitor (GS-0976), FGF19 (NGM-282), pemafibrate, emricasan, toll-like receptor 4 (TLR4) inhibitor (JKB-21), solithromycin, SSAO/VAP-1 inhibitor (BI 1467335), IMM-124E, galectin-3 inhibitor (GR-MD-02), and heat shock protein (HSP) 47 [97–108] to be addressed in future research questions. Here, MAP3K5 is linked to metabolic dysfunction-associated steatotic liver disease.